Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)

被引:154
作者
Drueeke, Tilman B. [1 ]
Parfrey, Patrick S. [2 ]
机构
[1] Univ Picardie Jules Verne, INSERM, Fac Med & Pharm, ERI 12,U1088,UFR Med & Pharm, F-80037 Amiens, France
[2] Hlth Sci Ctr, St John, NF, Canada
关键词
anemia; CKD; KDIGO guideline; recommendations; CLINICAL GUIDELINES; DISEASE;
D O I
10.1038/ki.2012.270
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for anemia in chronic kidney disease (CKD) is designed to assist health-care providers in treating CKD patients with anemia. A guideline is not intended to define a standard of care, and should not be construed as one, nor should it be interpreted as prescribing an exclusive course of management. It is intended to provide information and to allow the practitioner to make an informed decision, based on evidence and expert judgment. Every health-care professional making use of these recommendations is responsible for evaluating the appropriateness of applying them in any particular clinical situation. Owing to the general nature of a guideline, it is sometimes difficult to translate it to an individual patient's condition. As the primary goal is to improve patient care, we have decided to focus on practical clinical aspects of the KDIGO anemia guideline. Kidney International (2012) 82, 952-960; doi:10.1038/ki.2012.270; published online 1 August 2012
引用
收藏
页码:952 / 960
页数:9
相关论文
共 6 条
  • [1] The ethics of practice guidelines
    Berger, JT
    Rosner, F
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (18) : 2051 - 2056
  • [2] Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45
  • [3] EFFECT OF CLINICAL GUIDELINES ON MEDICAL-PRACTICE - A SYSTEMATIC REVIEW OF RIGOROUS EVALUATIONS
    GRIMSHAW, JM
    RUSSELL, IT
    [J]. LANCET, 1993, 342 (8883) : 1317 - 1322
  • [4] Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
    Mailankody, Sham
    Pfeiffer, Ruth M.
    Kristinsson, Sigurdur Y.
    Korde, Neha
    Bjorkholm, Magnus
    Goldin, Lynn R.
    Turesson, Ingemar
    Landgren, Ola
    [J]. BLOOD, 2011, 118 (15) : 4086 - 4092
  • [5] A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
    Pfeffer, Marc A.
    Burdmann, Emmanuel A.
    Chen, Chao-Yin
    Cooper, Mark E.
    de Zeeuw, Dick
    Eckardt, Kai-Uwe
    Feyzi, Jan M.
    Ivanovich, Peter
    Kewalramani, Reshma
    Levey, Andrew S.
    Lewis, Eldrin F.
    McGill, Janet B.
    McMurray, John J. V.
    Parfrey, Patrick
    Parving, Hans-Henrik
    Remuzzi, Giuseppe
    Singh, Ajay K.
    Solomon, Scott D.
    Toto, Robert
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21) : 2019 - 2032
  • [6] Clinical guidelines - Potential benefits, limitations, and harms of clinical guidelines
    Woolf, SH
    Grol, R
    Hutchinson, A
    Eccles, M
    Grimshaw, J
    [J]. BRITISH MEDICAL JOURNAL, 1999, 318 (7182) : 527 - +